Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Rena J. May"'
Autor:
Javier Pinilla-Ibarz, Rena J. May, Jaspreet Singh Jaggi, Marta Gómez-Nuñez, Mary Pao, Tao Dao, David A. Scheinberg
Publikováno v:
Leukemia Research. 30:1293-1298
The ability to reliably identify the peptides that can bind to MHC molecules is of practical importance for rapid vaccine development. Several computer-based prediction methods have been applied to study the interaction of MHC class I/peptide binding
Autor:
Rong H. Zhang, Tatyana Korontsvit, Javier Pinilla-Ibarz, Peter Maslak, David A. Scheinberg, Tao Dao, Rena J. May, Victoriya Zakhaleva
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(15 Pt 1)
Purpose: Wilms' tumor 1 protein (WT1), a transcription factor overexpressed in malignant mesothelioma, leukemias, and other solid tumors, is an ideal target for immunotherapy. WT1 class I peptide epitopes that were identified and shown to stimulate C
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 171(9)
Cryptococcus neoformans causes a life-threatening meningoencephalitis in AIDS patients. Mice immunized with a glycoconjugate vaccine composed of the glucuronoxylomannan (GXM) component of the cryptococcal capsular polysaccharide conjugated to tetanus
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 169(12)
Cryptococcus neoformans causes a life-threatening meningoencephalitis in a significant percentage of AIDS patients. Mice immunized with a glycoconjugate vaccine composed of the glucuronoxylomannan (GXM) component of the cryptococcal capsular polysacc
Autor:
Lieping Chen, Stanley Pillemer, Muaiad Kittaneh, Sara Brett, Martin Devenport, Rena J. May, Shannon Marshall, John D. Powderly, Jeffrey R. Infante, Jessica Houston Grice, Howard A. Burris, Margaret E. Fleming, Solomon Langermann, Drew M. Pardoll, James F. Smothers, Patricia LoRusso
Publikováno v:
Cancer Research. 73:LB-193
Background: AMP-224 is a recombinant Fc fusion protein that binds to the programmed death-1 (PD-1) receptor. This first-in-human study was designed to determine the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetic (PK) profile, pha
Autor:
Rena J. May, Victoriya Zakhaleva, Javier Pinilla, Peter Maslak, Tatyana Korontsvit, David A. Scheinberg, Tao Dao, Ronghua H. Zhang
Publikováno v:
Memorial Sloan Kettering Cancer Center
Wilms tumor protein 1 (WT1) is a transcription factor over-expressed in several types of leukemias and solid tumors, making it an ideal target for immunotherapy. A number of class I binding WT1 peptides have been identified and shown to stimulate CD8
Publikováno v:
Blood. 106:3512-3512
The recent identification of the JAK2 V617F mutation in myeloproliferative diseases including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis has the potential to serve as a new therapeutic target for these disorders. We hyp
Autor:
Tatyana Korontsvit, Victoriya Zakhaleva, Rena J. May, Tao Dao, Marta Gomez-Nunez, Javier Pinilla-Ibarz, David A. Scheinberg
Publikováno v:
Blood. 106:4483-4483
Major Histocompatibility Complex class I (MHC-I) molecules present antigenic peptides to T cells on the cell surface as a prerequisite for stimulating cytotoxic T cell response. Thus, the ability to reliably identify the peptides that can bind to MHC
Autor:
Marta Gomez-Nunez, Javier Pinilla-Ibarz, Tao Dao, Rena J. May, David A. Scheinberg, Tatyana Korontsvit, Victoriya Zakhaleva
Publikováno v:
Blood. 106:2868-2868
Intracellular processing of the breakpoint products of the bcr-abl fusion gene may generate novel peptides that, if capable of binding to HLA class I molecules, would be potential targets for a cytotoxic T lymphocyte (CTL) response. In humans, peptid